Neonatal gene transfer of Serca2a delays onset of hypertrophic remodeling and improves function in familial hypertrophic cardiomyopathy

• Published in: Journal of molecular and cellular cardiology Vol. 49; no. 6; pp. 993 - 1002
• Main Authors: Peña, James R, Szkudlarek, Ariani C, Warren, Chad M, Heinrich, Lynley S, Gaffin, Robert D, Jagatheesan, Ganapathy, del Monte, Federica, Hajjar, Roger J, Goldspink, Paul H, Solaro, R. John, Wieczorek, David F, Wolska, Beata M
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01-12-2010
• Subjects: Actin Cytoskeleton - drug effects; Actin Cytoskeleton - metabolism; Adenoviridae - genetics; Animals; Animals, Newborn; Atrial Natriuretic Factor - metabolism; Calcium-Binding Proteins - metabolism; Cardiomyopathy, Hypertrophic, Familial - physiopathology; Cardiomyopathy, Hypertrophic, Familial - therapy; Cardiovascular; Familial hypertrophic cardiomyopathy; Gene therapy; Gene Transfer Techniques; Genetic Therapy; Heart Function Tests; Hemodynamics - drug effects; Humans; Injections; Isoproterenol - pharmacology; Mice; Mice, Transgenic; Myocardial Contraction - drug effects; Myosin Heavy Chains - metabolism; Phosphorylation - drug effects; Protein Isoforms - metabolism; Rabbits; Sarcoplasmic Reticulum Calcium-Transporting ATPases - genetics; Sarcoplasmic Reticulum Calcium-Transporting ATPases - therapeutic use; Serca2; Treatment; Ventricular Remodeling - drug effects; Ventricular Remodeling - physiology; Familial hypertrophic cardiomyopathy; Serca2; Treatment; Gene therapy
• ISSN: 0022-2828; 1095-8584
• DOI: 10.1016/j.yjmcc.2010.09.010

Abstract Familial hypertrophic cardiomyopathy (FHC) is an autosomal dominant genetic disorder linked to numerous mutations in the sarcomeric proteins. The clinical presentation of FHC is highly variable, but it is a major cause of sudden cardiac death in young adults with no specific treatments. We tested the hypothesis that early intervention in Ca2+ regulation may prevent pathological hypertrophy and improve cardiac function in a FHC displaying increased myofilament sensitivity to Ca2+ and diastolic dysfunction. A transgenic (TG) mouse model of FHC with a mutation in tropomyosin at position 180 was employed. Adenoviral-Serca2a (Ad.Ser) was injected into the left ventricle of 1-day-old non-transgenic (NTG) and TG mice. Ad.LacZ was injected as a control. Serca2a protein expression was significantly increased in NTG and TG hearts injected with Ad.Ser for up to 6 weeks. Compared to TG-Ad.LacZ hearts, the TG-Ad.Ser hearts showed improved whole heart morphology. Moreover, there was a significant decline in ANF and β-MHC expression. Developed force in isolated papillary muscle from 2- to 3-week-old TG-Ad.Ser hearts was higher and the response to isoproterenol (ISO) improved compared to TG-Ad.LacZ muscles. In situ hemodynamic measurements showed that by 3 months the TG-Ad.Ser hearts also had a significantly improved response to ISO compared to TG-Ad.LacZ hearts. The present study strongly suggests that Serca2a expression should be considered as a potential target for gene therapy in FHC. Moreover, our data imply that development of FHC can be successfully delayed if therapies are started shortly after birth.